Symbols

UPB

Upstream Bio·NASDAQ

--(--)

UPB Profile

Upstream Bio, Inc.

A clinical biotechnology company focused on developing treatment methods for inflammatory diseases, with a particular emphasis on severe respiratory diseases

Industry

Biological Technology

Established Date

Listing Date

10/11/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.upstreambio.com

Security Type

Common stock

Office address

890 Winter Street Suite 200 Waltham MA 02451

Business

Introduction

Upstream Bio, Inc., was incorporated in Delaware in April 2021. They are a clinical-stage biotechnology company developing treatments for inflammatory diseases, initially focusing on severe respiratory diseases. They are developing verekitug, the only known antagonist currently in clinical development, targeting the thymic interstitial lymphopoietin (" TSLP ") receptor, a cytokine that is a clinically validated driver of inflammatory response located upstream of multiple signaling cascades affecting various immune-mediated diseases. Preclinical and clinical data to date show that verekitug has a highly potent inhibitory effect on TSLP receptors, which will translate into differentiated product features, including the potential to improve clinical outcomes, significantly extend dosing intervals and treat a wide range of patients.